Seeing Is Believing
Currently out of the existing stock ratings of Jason Zemansky, 23 are a BUY (57.5%), 14 are a HOLD (35%), 3 are a SELL (7.5%).
Analyst Jason Zemansky, currently employed at BAML, carries an average stock price target met ratio of 43.83% that have a potential upside of 14.52% achieved within 57 days.
Jason Zemansky’s has documented 78 price targets and ratings displayed on 9 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 01-Oct-2025.
Analyst best performing recommendations are on ESPR (ESPERION THERAPEUTICS).
The best stock recommendation documented was for ESPR (ESPERION THERAPEUTICS) at 3/16/2023. The price target of $1.5 was fulfilled within 6 days with a profit of $0.32 (17.58%) receiving and performance score of 29.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
$3
$1.79 (147.93%)
$3
1 years 27 days ago
(26-Sep-2024)
0/4 (0%)
$2.42 (417.24%)
Hold
$7
1 years 4 months 3 days ago
(20-Jun-2024)
1/3 (33.33%)
$0.45 (6.87%)
57
Sell
$1
$-0.21 (-17.36%)
$1.5
1 years 9 months 6 days ago
(17-Jan-2024)
6/6 (100%)
$-0.02 (-1.96%)
278
Buy
1 years 10 months 5 days ago
(18-Dec-2023)
1/1 (100%)
$32.69 (83.16%)
358
Buy
$9
$7.79 (643.80%)
2 years 5 months 12 days ago
(11-May-2023)
2/4 (50%)
$4.84 (116.35%)
178
Which stock is Jason Zemansky is most bullish on?
Which stock is Jason Zemansky is most reserved on?
What Year was the first public recommendation made by Jason Zemansky?